Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Stemcis is a French biotechnology company specializing in the development of innovative solutions for regenerative medicine and aesthetic surgery. The company focuses on the use of adipose-derived stem cells (ADSCs) and has developed proprietary technologies for the mechanical dissociation and enrichment of fat tissue. Their product portfolio includes specialized kits for fat grafting and cell isolation, such as Grasstem and Stemfill, which are used in reconstructive and cosmetic procedures. Stemcis aims to provide clinicians with standardized, efficient tools to harness the regenerative potential of a patient's own fat cells.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Stemcis.